New study in a small sample of physicians implies cost factor could be a big influence.
To this point, information about clinicians’ interest in prescribing biosimilars was largely limited to their comfort levels with the safety and efficacy of these agents compared with that of the originator products. They’ve shown a reasonable reluctance to prescribe biosimilars in patients whose disease activity has been stable with the use of an originator biologic, but have been more open to using them in patients who had not received biologics before. A new study in a small sample of physicians implies that the cost factor could be a bigger influence in their prescribing habits than suspected before.
A “microsurvey” from InCrowd of 150 physicians (30 dermatologists, endocrinologists, gastroenterologists, oncologists, and rheumatologists) was conducted in September 2016. Eighty-four percent are convinced that they will be prescribing biosimilars within 3 years.
Interestingly, the survey demonstrated that clinicians, too, are influenced by the cost savings biosimilars may bring—an area that was considered of interest mostly to payers. In their study, physicians would increasingly consider prescribing biosimilars as the cost difference with the originator product increased, from 28% with a 5% discount, 59% with a 15% discount, and 77% with a 25% discount. This may signal clinicians’ concern with the rising cost of biologics. The study authors did not specify whether these prescriptions would occur in a treatment-naïve or a switching scenario. However, three-quarters did admit that cost is important to their prescribing decision, but they would be unlikely to know what the patient’s cost share may be at the time of prescription.
Physician wariness of the biosimilars is still evident, according to InCrowd President and Co-founder Diane Hayes, who said, "Data reflect that during this time when biosimilars are of strong interest to insurers and health care systems for cost control, physicians are not rushing to issue a blank check for their substitution, and are keenly aware of their need to thoughtfully consider any such use." The survey did find that 67% would prohibit, at least in some cases, pharmacist-substitution of a prescribed originator product.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.